您好，欢迎来到试剂仪器网！ [登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > LJI308
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
LJI308
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
LJI308图片
CAS NO:1627709-94-7
包装与价格：
包装价格(元)
5mg电议
25mg电议

产品介绍
LJI308 是一种有效的泛核糖体 S6 激酶 (RSK) 抑制剂，对 RSK1、RSK2 和 RSK3 的 IC50 分别为 6 nM、4 nM 和 13 nM。 LJI308 在辐照、EGF 处理和表达 KRAS 突变的细胞中抑制 RSK (T359/S363) 和 YB-1 (S102) 的磷酸化。
Cas No.1627709-94-7
化学名2,6-difluoro-4-(4-(4-morpholinophenyl)pyridin-3-yl)phenol
Canonical SMILESFC1=C(O)C(F)=CC(C(C=NC=C2)=C2C3=CC=C(N4CCOCC4)C=C3)=C1
分子式C21H18F2N2O2
分子量368.38
溶解度DMF: 10 mg/ml,DMSO: 10 mg/ml,DMSO:PBS (pH 7.2)(1:9): 0.1 mg/ml
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IC50: 0.004 to 0.013 mM for RSK1, 2, and 3.

LJI308 is a potent and selective inhibitor of RSK. The p90 ribosomal S6 kinase (RSK) comprises a family of serine/threonine kinase which is expressed in various human cancers. RSK is the cytosolic substrate for the ERK (extracellular sianal-regulated kinase), involved in direct regulation of cell survival, proliferation, and cell polarity. Previous studies have demonstrated that RSK pathway is important for the growth and proliferation of cancer stem cells [1,2].

The IC50 values of LJI308 against RSK1, 2, and 3 were about 0.004 - 0.013 mmol/L. 10 μM LJI308 could bind to nearly 100% of the RSK2. LJI308 bound the N-termini of RSK1, RSK3, and RSK4 to a similar extent. LJI308 inhibited S6K1 with an IC50 of 0.8 mM. In both MDA-MB-231 and H358 cell lines, 1 μM and 10 μM LJI308 exihibited an inhibitory effect on colony formation and cell growth with a different sensitivity [1]. In HTRY-LT cell lines, treating with LJI308 (1-10 μM) after 4 or 8 days decreased the cell viability by up to 90%; while little to no effect was observed in the non-tumorigenic HTRZ cells [2].

LJI308, the RSK inhibitor, could be used in combination with conventional chemotherapy to overcome the drug resistance and improve survival in patients with the triple-negative breast cancer (TNBC) [2].

References:
[1].Aronchik I, Appleton B A, Basham S E, et al. Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers[J]. Molecular Cancer Research, 2014, 12(5): 803-812.
[2].Davies A H, Reipas K, Hu K, et al. Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells[J]. Oncotarget, 2015, 6(24): 20570.